Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in
 treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and
 with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.
Inclusion Criteria:

 -  Hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5, or 6 infection. Mixed GT and
 indeterminate GT may be acceptable.

 -  Aspartate aminotransferase (AST) to platelet ratio index (APRI) score of less than or
 equal to 1, at time of screening.

 -  Does not have current active hepatitis B virus infection defined as:

 -  positive hepatitis B surface antigen (HBsAg), OR

 -  hepatitis B virus (HBV) deoxyribonucleic acid (DNA) > lower limit of
 quantification (LLOQ) in subjects with isolated positive anti-hepatitis B core
 (HBc) (i.e., negative HBsAg and anti-hepatitis B surface[HBs])

 -  Platelets ≥ 150,000 cells/mm³

 -  Albumin ≥ lower limit of normal (LLN)

 -  Positive anti-HCV antibody (Ab) AND plasma HCV ribonucleic acid (RNA) viral load ≥
 1,000 IU/mL at Screening and for at least 6 months before Screening.

 -  No past history/evidence of cirrhosis.

 -  No history of hepatocellular carcinoma.

 -  Hepatitis C virus treatment-naïve (had not received a single dose of any approved or
 investigational anti-HCV medication).

 -  If female, the subject must not be pregnant, breastfeeding, or considering becoming
 pregnant during the study and for 30 days after the last dose of study drug.